AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after their $18.5B obesity alliance and two deals in previous years.
Less than six months after lining up one of the largest biobucks packages in industry history, AstraZeneca is returning to the same Chinese partner for …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
China's CSPC and AstraZeneca sign $1.77b drug development deal
Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance - AstraZeneca (NYSE:AZ
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
Chinese drugmaker CSPC Pharmaceutical Group said on Thursday that it had entered a strategic collaboration with AstraZeneca to…
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb…
Drugmaker expands push into fast-growing market
AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B…
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA,…
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a…
